Balchem Corporation — Q2 2012 Form 10-Q
Business context and period: Unaudited results for the quarter and six months ended June 30, 2012; amounts are in thousands of dollars except per-share data. Balchem develops and sells specialty ingredients and products through Specialty Products, Food, Pharma & Nutrition, and Animal Nutrition & Health.
Financial performance
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Net sales | $79,014 | $74,687 | $155,217 | $147,695 |
| Gross margin | $22,584 | $21,761 | $43,742 | $42,541 |
| Earnings from operations | $14,825 | $14,059 | $28,500 | $27,357 |
| Net earnings | $9,972 | $9,572 | $19,240 | $18,484 |
| Diluted EPS | $0.33 | $0.32 | $0.64 | $0.61 |
- Q2 sales grew 5.8%, operating earnings 5.4%, and net earnings 4.2% year over year. Six-month sales rose 5.1%, operating earnings 4.2%, and net earnings 4.1%.
- Gross margin was 28.6% in Q2 versus 29.1% a year earlier; six-month gross margin was 28.2% versus 28.8%. Operating margin was 18.8% in Q2, unchanged year over year, and 18.4% for six months versus 18.5%.
- Six-month operating cash flow was $31,223, up from $17,117; capital expenditures were $3,198. Cash increased to $138,060 from $114,781 at year-end 2011.
- At June 30, current assets were $198,259 and current liabilities $29,968; reported working capital was $168,291. Total debt was $785 ($696 current and $89 long-term), down from $1,410 at December 31, 2011.
Changes, segment trends, and notable items
- Animal Nutrition & Health, the largest segment, grew Q2 sales 5.8%; specialty ingredients rose 36%, supported by higher demand for rumen-protected products. Food, Pharma & Nutrition sales rose 8.1%, driven by human choline, while lower food-market volumes partly offset growth. Specialty Products sales rose 3.6%.
- Management suspended sales of AminoShure-L, 52% lysine, after research found lysine bioavailability below design expectations. The filing reports no safety concerns. Related sales credits were approximately $1,000, with an estimated net gross-margin impact of about $800 and related costs of $160.
- Higher raw-material costs, particularly petrochemical inputs used in choline, and the product suspension pressured gross margin. Management cited volume growth, pricing actions, and operational efficiencies as offsets.
- Cash-flow improvement reflected higher earnings and favorable working-capital changes, including income taxes. Foreign-currency translation reduced comprehensive income; Q2 translation adjustment was a loss of $792.
Outlook, liquidity, and risks
- No quantitative earnings or revenue guidance was provided. Management expects operations to generate sufficient cash to fund working capital and necessary capital investments and said it is pursuing acquisition candidates; it may seek financing for acquisitions or other needs.
- Both short-term revolving credit facilities matured May 31, 2012 and were not renewed. The remaining European term loan matures May 1, 2014; its rate was 1.39% at June 30. Management reported no known current or pending liquidity demands expected to materially affect liquidity.
- Raw-material and foreign-exchange exposures remain; the company manages them where possible through pricing and operations and reported no derivatives or hedging instruments. A 100-basis-point rate change on period-end borrowings would affect annual interest expense by approximately $7.
- Contingencies include environmental monitoring/remediation matters at Slate Hill, New York, and the Verona, Missouri Superfund site. Management believes litigation, claims, and assessments will not materially affect financial position, results, or liquidity. The filing reports no material change in the risk factors identified in the 2011 Form 10-K.
Important facts for investors to verify
- Progress and financial consequences of the AminoShure-L suspension, including any further credits, costs, or replacement product plans.
- Whether raw-material pricing and product mix continue to compress gross margins, especially in Animal Nutrition & Health.
- Sustainability of operating cash flow, given the significant contribution from working-capital and income-tax movements in the first half.
- Acquisition plans and any funding needs following the nonrenewal of the revolving facilities.
- Developments in environmental matters and the approximately $2,092 of unrecognized tax benefits, for which management anticipated no material change over the next 12 months.